



Welcome to the 2017 Annual Meeting of the Consortium of Multiple Sclerosis Centers. Included in this handout you will find credit information, learning objectives, and disclosure of financial relationships for faculty, planners, and reviewers.

ACCREDITATION/CREDIT DESIGNATION STATEMENTS

In order to successfully complete this knowledge-based continuing education activity, the participant must register for the activity, attend the educational sessions, and complete the online evaluation and claim for credit. Detailed instructions are available at the CMSC Registration Desk and will be emailed to you after the meeting.

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Consortium of Multiple Sclerosis Centers (CMSC), Nurse Practitioner Alternatives (NPA), and The France Foundation.

PHYSICIANS



THE CONSORTIUM OF
MULTIPLE SCLEROSIS CENTERS

The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the ACCME to provide continuing medical education for physicians.

The CMSC designates this live activity for a maximum of 21.25 *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PAs

The American Academy of Physician Assistants (AAPA) accepts certificates of participation for education activities certified for *AMA PRA Category 1 Credit(s)*TM from organizations accredited by ACCME.

NURSES



NPA

Nurse Practitioner Alternatives (NPA) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is jointly provided by NPA, CMSC, and The France Foundation.

NPA designates this live activity for a maximum of 21.25 Continuing Nursing Education Credits.

Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has declared no relevant financial relationships with business and industry.

Code: CMSC052417

PHARMACISTS



The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award up to 21.25 contact hours (2.13 CEUs) to pharmacists who (1) complete the activity and (2) submit a passing posttest (> 70%) and evaluation form via www.ff-ce.org. There is no fee to participate in this activity. This is a knowledge-based educational activity. The sessions offering ACPE credit are designated in a supplemental registration handout with a Universal Activity Number (UAN) and hours of credit, which is available at the CMSC Registration Desk. Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the live activity. To ensure your credit fulfillment, you must submit your posttest, evaluation and credit request via www.ff-ce.org NO LATER THAN July 10, 2017. Credit requests made more than 60 days after the activity WILL BE REJECTED BY CPE Monitor, and are beyond our control. For more information about CPE Monitor, visit <http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service/>.

SOCIAL WORKERS

This program is approved by the National Association of Social Workers (Approval #886535345-9404) for 20 continuing education contact hours.

PSYCHOLOGISTS



The Consortium of Multiple Sclerosis Centers is approved by the American Psychological Association to sponsor continuing education for psychologists. The Consortium of Multiple Sclerosis Centers maintains responsibility for this program and its content.

CMSC offers 45 total contact hours of continuing education in psychology over the course of this program. Because many accredited sessions are offered simultaneously, APA affiliated attendees may claim a maximum of 16.25 CE credits for their participation.

OCCUPATIONAL THERAPISTS



The Consortium of Multiple Sclerosis Centers is approved by the American Occupational Therapy Association, Inc. (AOTA) as a provider of continuing occupational therapy education. The Consortium of Multiple Sclerosis Centers maintains responsibility for this program and its content.

CMSC offers more than 63 total contact hours of continuing education in Occupational Therapy over the course of this program. Because many accredited sessions are offered simultaneously, AOTA affiliated attendees may claim a maximum of 1.8 AOTA CEU's (18 contact hours) for this activity.

CERTIFICATE OF PARTICIPATION

A Certificate of Attendance will be given upon completion of course requirements enabling you to register your credit with the appropriate licensing boards or associations. You may apply for other accreditations using the procedure established by the specific organization.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT

This live activity is supported in part by educational grants received from the following commercial entities:

- AbbVie Inc.
- Biogen
- Celgene Corporation
- Mylan, Inc.
- Teva Pharmaceuticals

TARGET AUDIENCE

The target audience for the annual meeting includes all healthcare professionals, pharmacists, researchers, and advocates who are involved in multiple sclerosis care and research.

TRACK LEARNING OBJECTIVES

The CMSC Continuing Education Committee has identified educational gaps in nine content areas and has solicited educational sessions in each of these tracks. In addition to overall objectives, learning objectives specific to each of those tracks were developed.

Basic Science/Environmental Factors (SC)

- Review the diagnostic criteria, phenotypes, and variants of MS to promote accurate diagnosis, initiation of appropriate therapy and monitoring of outcomes.
- Identify the roles and interactions of genetics and epigenetics, the microbiome, environmental factors, age, comorbidities, and risk behaviors as factors contributing to pathogenesis and the course of MS.

Psychosocial: Cognition, Depression (CG)

- Appropriately integrate tools and strategies into patient assessment that improve the ability to differentiate between cognitive problems, depression, and related psychosocial issues.
- Identify professional and community resources that support the work of the mental health team in providing comprehensive care to patients with MS.
- Incorporate information obtained through appropriate assessments into therapeutic plans of care for each identified area of concern.

Comprehensive Care (CC)

- Examine the various models of care in MS and the roles and responsibilities of the team members in order to adapt the most appropriate model for a given practice setting.
- Integrate the complex processes that support the provision of comprehensive care in MS into effective practices and centers providing evidence-based MS care.

Disease Management (DX)

- Integrate information about the mechanisms underlying MS relapses, progression, and gray and white matter pathology as the basis for monitoring and treating the disease.
- Summarize methods to monitor treatment outcomes including patient self-report, automated self-assessment, new clinician reported outcomes, imaging and biomarkers to optimize their utilization in clinical practice and research.

TRACK LEARNING OBJECTIVES (Cont'd)

Nursing (RN)

- Analyze and integrate the conceptual framework under which MS nurses construct individualized interventions and monitor outcomes in the care of patients with MS.
- Evaluate current nursing practice in MS as compared to models of care utilized in a variety of settings in North America and internationally.
- Incorporate specific and evidence-based nursing skills into the development of plans for individualized care of patients and families affected by MS.

Rehabilitation (RH)

- Integrate rehabilitative strategies into the multidisciplinary management of the sequelae of MS which promote improvements and optimize patients' function and quality of life.
- Identify MS-specific screening techniques that facilitate individualized and targeted rehabilitation services.

Symptomatic Management (SX)

- Analyze common symptoms of MS and their appropriate pharmacologic and non-pharmacologic interventions in order to develop strategies designed to produce disease control and maximize function.
- Identify assessment techniques to isolate those factors that affect the manifestation of the complex symptomatology of MS and differentiate between acute and chronic MS symptoms.

Skills Development (SK)

- Critically examine how the expert patient, news media, and social media affect the relationships between patients with MS, healthcare professionals, and researchers.
- Incorporate acquired information into professional practice skills that enhance comprehensive MS care and better serve patients, families, and colleagues.

Research (RS)

- Synthesize emerging data on treatment strategies, such as early treatment, switching therapies, treating to achieve No Evidence of Disease Activity (NEDA), personalized treatment, and post-marketing monitoring of safety and efficacy in order to promote continuing insights into disease pathology, course, and management.
- Review the design and outcomes of clinical trials in relapsing and progressive MS and disseminate this information to prepare clinicians to evaluate trial quality and, where appropriate, integrate findings into clinical practice.

SESSIONS, CREDIT TYPES AND NUMBER OF CREDITS OFFERED

Wednesday, May 24th

John F. Kurtzke Memorial Lecture: MS Comprehensive Care-A Team Sport

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 0.75

Clinical Course 1

MJ for MS?—An MS Health Professional's Guide to Cannabis-Part 1

Credit types: ACPE, APA, CME, CNE, NASW; Amount: 1.5

Clinical Course 2

Review of Pharmacology Concepts Part 1: The Evolution of Disease Modifying Therapies

Credit types: ACPE, CME, CNE; Amount: 1.5

Clinical Course 3

Models of Rehabilitation Care

Credit type: AOTA; Contact Hours: 1.5

Clinical Course 4

Behavioral Medicine: Lifeline for MS

Credit types: ACPE, APA, CME, CNE, NASW; Amount: 1.5

Clinical Courses 5

The Foundation of MS Nursing: Building your Practice-Part I

Credit type: CNE; Amount: 1.5

Clinical Course 6

CMSC MRI Guidelines: A 2017 Update

Credit types: CME, CNE; Amount: 1.5

Clinical Course 7

How to Perform the EDSS

Credit types: CME, CNE; Amount: 1.5

Clinical Course 8

Basic Immunology for the Non-Immunologist

Credit types: ACPE, APA, CME, CNE; Amount: 1.5

Clinical Course 9

MJ for MS?—An MS Health Professional's Guide to Cannabis-Part 2

Credit types: ACPE, CME, CNE, NASW; Amount: 1.5

Clinical Course 10

Review of Pharmacology Concepts Part 2: Beyond the DMTs

Credit types: ACPE, CME, CNE; Amount: 1.5

Clinical Course 11

Translating the Latest Motor Learning Evidence into Practice

Credit type: AOTA; Contact hours: 1.5

Wednesday, May 24th (Cont'd)

Clinical Course 12

There's an App for That: Novel Ways to Manage Symptoms of MS

Credit types: APA, CME, CNE, NASW; Amount: 1.5

Clinical Course 13

The Foundation of MS Nursing: Building your Practice-Part 2

Credit type: CNE; Amount: 1.5

Clinical Course 14

CMSC MRI Guidelines: A 2017 Update

Credit types: CME, CNE; Amount: 1.5

Clinical Course 15

How to Perform the EDSS

Credit types: CME, CNE; Amount: 1.5

Clinical Course 16

Advanced Immunology for the Non-Immunologist

Credit types: ACPE, CME, CNE; Amount: 1.5

Meet the Professor Dinner: What is New in MS Treatment-The Benefits in Everyday Clinical Practice

Type of credit offered: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 1.0

Thursday, May 25th

Presidential Lecture: New McDonald Criteria

Credit types: ACPE, CME, CNE; Amount: 0.75

Fundamentals of MS Care: A Case-based Approach to Disease Management 2017 – Part 1

Credit types: ACPE, AOTA, CME, CNE, NASW; Amount: 2.75

Current Topics and Trends in MS Rehabilitation – Part 1

Credit types: AOTA, CME, NASW; Amount: 2.75

Core Concepts for the MS Nurse: International Case Based Perspectives

Credit types: ACPE, CNE; Amount: 2.5

Symposium 1

CNS Repair and Ways to Measure It

Credit types: ACPE, CME, CNE; Amount: 2.5

Symposium 2

Unique Wellness Approaches to Progressive MS

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 2.5

Symposium 3

Debates over Controversies in MS

Credit types: CME, CNE; Amount: 2.5

Thursday, May 25th (Cont'd)

Symposium 4

Cognition in MS: Update on Assessment, Neuropathology and Rehabilitation

Credit types: AOTA, APA, CME, CNE, NASW; Amount: 2.5

Fundamentals of MS Care: A Case-based Approach to Disease Management 2017 – Part 2

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 2.5

Current Topics and Trends in MS Rehabilitation – Part 2

Credit types: AOTA, APA, CME, NASW; Amount: 2.5

Symposium 5

Role of T Cells and B Cells in MS Pathogenesis-Part 1

Credit types: ACPE, CME, CNE; Amount: 2.5

Symposium 6

Pediatric MS

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 2.5

Symposium 7

Use of Lipid Metabolism Blockers and Modifiers for the Treatment of MS: A Paradigm Shift

Credit types: ACPE, CME, CNE; Amount: 2.5

Symposium 8

Update on Gender Issues in MS

Credit types: ACPE, APA, CME, CNE, NASW; Amount: 2.5

Symposium 9

Interdisciplinary Approach to Managing Sexuality Issues in Patients with MS

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 2.5

Symposium 10

Building Opportunities and Connecting Women MS Neurologists

Credit types: CME, CNE; Amount: 2.5

Friday, May 26th

John Whitaker Memorial Lecture: How Research on Pediatric MS Can Inform Thoughts on MS Pathogenesis

Credit types: ACPE, CME, CNE; Amount: .75

Whitaker Track

Credit types: CME, CNE; Amount: 2.75

Fundamentals of MS Care: A Case-based Approach to Symptom Management 2017 – Part 3

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 2.75

Current Topics and Trends in MS Rehabilitation – Part 3

Credit types: AOTA, CME, NASW; Amount: 2.75

Symposium 11

Function of Myeloid Cells in CNS Inflammation with a Focus on Microglia Cells and CNS-invading Macrophages During MS

Credit types: CME, CNE; Amount: 2.5

Friday, May 26th (Cont'd)

Symposium 12

A New Paradigm of MS Care: Optimizing Health through the Integration of Lifestyle, Alternative, and Conventional Medicine

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 2.5

Symposium 13

Depression & Suicide in MS: What We Know and What We Can Do About It

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 2.5

Symposium 14

Effective Management Strategies for Complex Symptoms of MS

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 2.5

Symposium 15

Role of T Cells and B Cells in MS Pathogenesis – Part 2

Credit types: ACPE, CME, CNE; Amount: 2.75

Fundamentals of MS Care: A Case-based Approach to Symptom Management 2017 – Part 4

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 2.75

Platform Presentations: Psychosocial: Cognition, Depression

Credit types: AOTA, APA, CME, CNE, NASW; Amount: 2.0

Platform Presentations: Disease Management, Imaging and Therapeutics

Credit types: ACPE, AOTA, CME, CNE; Amount: 2.0

Platform Presentations: Rehabilitation Interventions

Credit types: AOTA, CME; Amount: 2.0

Platform Presentations: Comprehensive Care in MS and Symptom Management

Credit types: ACPE, AOTA, CME, CNE; Amount: 2.0

WORKSHOPS

Workshop 1

Using Digital Tools to Enhance MS Care

Credit types: ACPE, AOTA, CME, CNE, NASW; Amount: 1.5

Workshop 2

Empowering Patients by Making Them Part of the Engineering Team

Credit types: AOTA, APA, CME, CNE, NASW; Amount: 1.5

Workshop 3

Treating Individuals and Providing Population Based Care Using Large Data

Credit types: CME, CNE; Amount: 1.5

Workshop 4

Evaluating Potential Clinical Trials: What to Know

Credit types: ACPE, CME, CNE; Amount: 1.5

Friday, May 26th (Cont'd)

Workshop 5

The Collaborative Approach to MS Care

Credit types: ACPE, AOTA, CME, CNE, NASW; Amount: 1.5

Workshop 6

Scales and Measures in MS

Credit types: AOTA, APA, CME, CNE, NASW; Amount: 1.5

Workshop 7

Neuromyelitis Optica Spectrum Disorders

Credit types: ACPE, CME, CNE; Amount: 1.5

Workshop 8

What Have We Learned from Registries?

Credit types: CME, CNE; Amount: 1.5

Workshop 9

Wellness in MS: Methodology for Clinical Studies

Credit types: AOTA, APA, CME, CNE, NASW; Amount: 1.5

Saturday, May 27th

Donald Paty Memorial Lecture: Induction or Aggressive Treatment for Multiple Sclerosis-Is it Right for Most, Some or No Patients?

Credit types: ACPE, CME, CNE, NASW; Amount: .75

Current Topics and Trends in MS Rehabilitation – Part 4

Credit types: AOTA, CME, NASW; Amount: 2.75

Symposium 16

Microbiome

Credit types: CME, CNE; Amount: 2.75

Symposium 17

Comorbidities in Multiple Sclerosis

Credit types: ACPE, AOTA, APA, CME, CNE, NASW; Amount: 2.75

Symposium 18

BEAT-MS: Who, What, Why, When and Where?

Credit types: ACPE, CME, CNE; Amount: 2.75

Symposium 19

Informal Caregiving: From Theory to Practice

Credit types: AOTA, APA, CME, CNE, NASW; Amount: 2.75

Symposium 20

DMT Treatment Decisions in MS: Sorting out the Data

Credit types: ACPE, CME, CNE, NASW; Amount: 2.5

DISCLOSURE OF FINANCIAL RELATIONSHIPS

It is the policy of CMSC, NPA, and The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, planning committee members, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their significant other have within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.

DISCLOSURE OF UNLABELED USE

CMSC, NPA, and The France Foundation require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

CONTINUING EDUCATION COMMITTEE, PLANNERS, REVIEWERS AND STAFF DISCLOSURES

Jacquelyn Bainbridge, PharmD, FCCP has disclosed the following relevant financial relationship(s): Contracted Research: Supernus Pharmaceuticals.

Patricia Bobryk, MHS, PT, MSCS, ATP has disclosed no relevant financial relationships.

Marty Buonato has disclosed no relevant financial relationships.

Lisa DeSantis, JD has disclosed no relevant financial relationships.

Constance B. Easterling, RN, MSN, ARNP, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Bayer Healthcare Pharmaceuticals; Speakers Bureau: Genentech, Acorda Therapeutics, EMD Serono, Genzyme, a Sanofi Company, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, Teva Pharmaceuticals.

Frederick W. Foley, PhD has disclosed no relevant financial relationships.

Corey C. Ford, MD, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Teva Pharmaceuticals, Novartis.

Vonda L. Ford, PharmD, MSCS has disclosed no relevant financial relationships.

Myla D. Goldman, MD, Msc has disclosed the following relevant financial relationship(s): Consulting Fee: EMD Serono, Novartis, Sanofi Genzyme.

June Halper, MSN, APN-C, MSCN, FAAN has disclosed no relevant financial relationships.

Colleen Harris, MN, NP, MSCN, MSCS has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Sanofi Genzyme, Roche, Novartis.

Jodie K. Haselkorn, MD, MPH has disclosed no relevant financial relationships.

Deborah Miller, PhD, LISW, MSAA has disclosed no relevant financial relationships.

Amy Perrin Ross, APN, MSN, CNRN, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Teva, EMD Serono, Novartis, Genzyme, Genentech, Celgene, Mallinckrodt, Acorda.

Michael K. Racke, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Coherus, Eisai, Cipla; Contracted Research: Genentech, Novartis, Actelion, Immune Tolerance Network; Honoraria as Editor-in-Chief of Journal of Neuroimmunology.

Susan Ratti has disclosed no relevant financial relationships.

Laurie Scudder, DNP, NP has disclosed no relevant financial relationships.

Christine Smith, OTR/L, MSCS has disclosed no relevant financial relationships.

Tina Trott has disclosed no relevant financial relationships.

Bryan D. Walker, MHS, PA-C has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, EMD Serono, Sanofi Genzyme.

Mitchell T. Wallin, MD, MPH has disclosed no relevant financial relationships.

Jeffrey Wilken, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Sanofi Genzyme; Contracted Research: Sanofi Genzyme, Biogen, Novartis.

SCIENTIFIC ABSTRACT REVIEW COMMITTEE DISCLOSURES

Maria Victoria Ali, MSCN, NP has disclosed no relevant financial relationships.

Dorothea Cassidy-Pfohl, RN, BS, MSCN has disclosed the following relevant financial relationship(s): Speakers Bureau: Acorda, Sanofi Genzyme.

Kathleen Czuba, SLP has disclosed no relevant financial relationships.

Robert Fallis, MD, MSCS has disclosed no relevant financial relationships.

Cindy Gackle, OTR/L, MSCS has disclosed no relevant financial relationships.

Myla D. Goldman, MD, Msc has disclosed the following relevant financial relationship(s): Consulting Fee: EMD Serono, Novartis, Sanofi Genzyme.

Ajay Gupta, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Bayer Healthcare Pharmaceuticals; Speakers Bureau: Bayer Healthcare Pharmaceuticals, Biogen, Mallinckrodt, Sanofi Genzyme.

June Halper, MSN, APN-C, MSCN, FAAN has disclosed no relevant financial relationships.

Colleen Harris, MN, NP, MSCN, MSCS has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Sanofi Genzyme, Roche, Novartis.

Rock Heyman, MD has disclosed no relevant financial relationships.

Gloria Hou, MD has disclosed no relevant financial relationships.

Sue Kushner, MS, PT has disclosed the following relevant financial relationship(s): Consulting Fee: Acorda.

Beverly A. Layton, RN, CCRC, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Bayer Healthcare Pharmaceuticals, Biogen, Sanofi Genzyme; Speakers Bureau: Bayer Healthcare Pharmaceuticals, Biogen, Sanofi Genzyme.

Deborah M. Miller, PhD, LISW, MSAA has disclosed the following relevant financial relationship(s): Consulting Fee: Hoffman-Roche.

Amy Perrin Ross, APN, MSN, CNRN, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Teva, EMD Serono, Novartis, Genzyme, Genentech, Celgene, Mallinckrodt, Acorda.

Cynthia Sullivan, PhD has disclosed the following relevant financial relationship(s): Contracted Research: Sanofi Genzyme.

Gloria von Geldern, MD has disclosed no relevant financial relationships.

Jeffrey Wilken, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Sanofi Genzyme; Contracted Research: Sanofi Genzyme, Biogen, Novartis.

Annette Wundes, MD has disclosed no relevant financial relationships.

FACULTY DISCLOSURES

Stephanie Agrella, MSN, APRN, ANP-BC, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Sanofi Genzyme, Genentech, Biogen; Speakers Bureau: Teva Pharmaceuticals, Sanofi Genzyme, Novartis, EMD Serono, Biogen, Acorda Therapeutics.

Jack Antel, MD has disclosed no relevant financial relationships.

Jacquelyn Bainbridge, PharmD, FCCP has disclosed the following relevant financial relationship(s): Contracted Research: Supernus Pharmaceuticals.

Brenda Banwell, MD, FAAP, FRCPC has disclosed the following relevant financial relationship(s): Consulting Fee: Novartis.

Sergio Baranzini, PhD has disclosed the following relevant financial relationship(s): Speakers Bureau: EMD Serono, Sanofi Genzyme.

Burkhard Becher, PhD has disclosed no relevant financial relationships.

Ralph Benedict, PhD has disclosed the following relevant financial relationship(s): Royalty: Psychological Assessment Resources; Consulting Fee: Abbvie, Biogen, Genzyme, a Sanofi Company, Novartis, Roche, Sanofi Aventis, Teva

Pharmaceuticals; Speakers Bureau: EMD Serono; Contracted Research: Acorda Therapeutics, Biogen, Mallinckrodt Pharmaceuticals, Genzyme, a Sanofi Company.

Susan Bennett, PT, DPT has disclosed the following relevant financial relationship(s): Speakers Bureau: Acorda Therapeutics.

Bonnie Blain, RN, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Genzyme, a Sanofi Company, Novartis, EMD Serono.

Valerie Block, PT, DPTSc has disclosed no relevant financial relationships.

Patricia Bobryk, MHS, PT, MSCS, ATP has disclosed no relevant financial relationships.

Aaron Boster, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Genentech, Medtronic Inc., Novartis, Sanofi Genzyme, Teva Pharmaceuticals; Speakers Bureau: Biogen, Genentech, Medtronic Inc., Novartis, Sanofi Genzyme, Teva Pharmaceuticals.

Dennis Bourdette, MD has disclosed no relevant financial relationships.

Riley Bove, MD has disclosed no relevant financial relationships.

James Bowen, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Acorda Therapeutics, Biogen, EMD Serono, Genzyme, a Sanofi Company, Genentech, Novartis, Roche, Teva Pharmaceuticals; Speakers Bureau: Acorda Therapeutics, Biogen, EMD Serono, Genentech, Novartis, Teva Pharmaceuticals; Contracted Research: Acorda Therapeutics, Biogen, Genentech, Novartis, Roche, Sanofi Aventis, Glaxo Smith Kline; Ownership Interest: (Spouse/Partner) Amgen.

Allen Bowling, MD, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, EMD Serono, Genentech, Genzyme, a Sanofi Company, Teva Pharmaceuticals; Speakers Bureau: Acorda Therapeutics, Biogen, EMD Serono, Genentech, Genzyme, a Sanofi Company, Mallinckrodt Pharmaceuticals, Teva Pharmaceuticals; Contracted Research: Biogen, EMD Serono, Genentech, Mallinckrodt Pharmaceuticals.

David Brandes, MS, MD, FAAN, MSCS has disclosed no relevant financial relationships.

Brenda Brelje, RN, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Sanofi Genzyme, Genentech; Speakers Bureau: Novartis, Sanofi Genzyme.

Lacey Bromley, PT, DPT, NCS, MSCS has disclosed the following relevant financial relationship(s): Speakers Bureau: Acorda Therapeutics.

Therese Burke, RN, CNC, MSCN has disclosed no relevant financial relationships.

Gabe Byars, OTR/L has disclosed no relevant financial relationships.

Michelle Cameron, MD, PT, MCR has disclosed no relevant financial relationships.

Tracy Carrasco, OT/L, MSCS, CLT has disclosed no relevant financial relationships.

Lucille Carriere, PhD has disclosed no relevant financial relationships.

Jonah Chan, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Inception Sciences.

Tanuja Chitnis, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Bayer Healthcare Pharmaceuticals, Novartis; Contracted Research: Verily, EMD Serono.

Amrish Chourasia, PhD has disclosed no relevant financial relationships.

Jeffrey Cohen, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Adamas, Merck, Mallinckrodt Pharmaceuticals, Novartis, Receptos; Other: Editor, Mult Scler J - ETC.

Marco Colonna, MD has disclosed no relevant financial relationships.

Giancarlo Comi, MD has disclosed no relevant financial relationships.

Angelique Corthals, PhD has disclosed no relevant financial relationships.

Kathleen Costello, MS, ANP-BC, MSCN has disclosed no relevant financial relationships.

Laura Cox, PhD has disclosed no relevant financial relationships.

Patricia Coyle, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Acorda Therapeutics, Biogen, Bayer Healthcare Pharmaceuticals, Genentech, Genzyme, a Sanofi Company, Mallinckrodt Pharmaceuticals, Novartis, Roche, Sanofi Genzyme, Teva Pharmaceuticals; Contracted Research: Novartis, Genentech, Opexa, Actelion.

Anne Cross, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Abbvie, Bayer Healthcare Pharmaceuticals, Biogen, EMD Serono, Genentech, Genzyme, a Sanofi Company, Novartis, Roche, Teva Pharmaceuticals; Contracted Research: Genentech.

William Culpepper, PhD, MA has disclosed no relevant financial relationships.

Gary Cutter, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Genzyme, a Sanofi Company, Genentech, Novartis, Roche, Teva Pharmaceuticals, Atara Biotherapeutics, Bioeq GmbH, Cerespir Inc, Consortium of MS Centers (grant), Innate Therapeutics, Janssen Pharmaceuticals, Klein-Buendel Incorporated, Medimmune, Medday, Nivalis, Opexa Therapeutics, Savara Inc., Somahlution, Transparency Life Sciences, TG Therapeutics; Other: Data and Safety Monitoring Boards - AMO Pharmaceuticals, Apotek, Gilead Pharmaceuticals, Horizon Pharmaceuticals, Modigenetech/Prolor, Merck, Merck Pfizer, Opko Biologics, Neuren, Sanofi-Aventis, Reata Pharmaceuticals, Receptos/Celgene, Teva Pharmaceuticals, NHLBI (Protocol Review committee), NICHD (OPRU oversight committee).

Kate Czuba, CCC-SLP/L, MSCS has disclosed no relevant financial relationships.

John DeLuca, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen; Speakers Bureau: EMD Serono.

Samantha Domingo, PsyD has disclosed no relevant financial relationships.

Michelle Drerup, PsyD has disclosed no relevant financial relationships.

Constance Easterling, RN, MSN, ARNP, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Bayer Healthcare Pharmaceuticals; Speakers Bureau: Genentech, Acorda Therapeutics, EMD Serono, Genzyme, a Sanofi Company, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, Teva Pharmaceuticals.

Dawn Ehde, PhD has disclosed no relevant financial relationships.

Morgan Faeder, MD, PhD has disclosed no relevant financial relationships.

Anthony Feinstein, MD, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Sanofi Genzyme; Speakers Bureau: Teva Pharmaceuticals, EMD Serono, Novartis, Biogen.

Mary Kay Fink, MSN, ARNP, MSCN has disclosed the following relevant financial relationship(s): Speakers Bureau: Acorda Therapeutics, Biogen, EMD Serono, Genentech, Genzyme, a Sanofi Company, Novartis, Sanofi Genzyme, Teva Pharmaceuticals.

Marcia Finlayson, PhD, OTR has disclosed no relevant financial relationships.

Kathryn Fitzgerald, ScD, ScM has disclosed no relevant financial relationships.

Frederick Foley, PhD has disclosed no relevant financial relationships.

Corey Ford, MD, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Teva Pharmaceuticals, Novartis.

Edward Fox, MD, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Acorda Therapeutics, Bayer Healthcare Pharmaceuticals, Biogen, EMD Serono, Genentech, Genzyme, a Sanofi Company, Novartis, Teva Pharmaceuticals; Speakers Bureau: Acorda Therapeutics, Biogen, EMD Serono, Genentech, Genzyme, a Sanofi Company, Novartis, Teva Pharmaceuticals; Contracted Research: Biogen, Chugai, Genentech, Genzyme, a Sanofi Company, Novartis, Teva Pharmaceuticals, TG Therapeutics.

Nora Fritz, PhD, PT, DPT, NCS has disclosed no relevant financial relationships.

Helen Genova, PhD has disclosed no relevant financial relationships.

George Georges, MD has disclosed no relevant financial relationships.

Gavin Giovannoni, MBBCh, PhD, FCP (South Africa), FRCP, FRCPath has disclosed the following relevant financial relationship(s): Consulting Fee: Abbvie, Biogen, EMD Serono, Genzyme, a Sanofi Company, Novartis, Roche, Sanofi Genzyme, Teva Pharmaceuticals; Speakers Bureau: Abbvie, Biogen, EMD Serono, Genzyme, a Sanofi Company, Novartis, Roche, Teva Pharmaceuticals; Contracted Research: Biogen, Novartis, Sanofi Genzyme; Ownership Interest: Canbex.

Andrew Goodman, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Abbvie, Acorda Therapeutics, Bayer Healthcare Pharmaceuticals, Mylan Inc., Novartis, Sanofi Genzyme, Atara, Celgene; Contracted Research: Acorda Therapeutics, Biogen, EMD Serono, Novartis, Roche, Sanofi Genzyme, Teva Pharmaceuticals, Avanir, Sun Pharma.

May Han, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Pfizer, Biogen, Sanofi Genzyme.

Claire Hara-Cleaver, RN, MSN, ANP, CS has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Novartis; Speakers Bureau: Genentech.

Timothy Harlan, MD, FACP has disclosed no relevant financial relationships.

Colleen Harris, MN, NP, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Sanofi Genzyme, Roche, Novartis.

Felecia Hart, PharmD has disclosed the following relevant financial relationship(s): Contracted Research: Supernus Pharmaceuticals.

Jodie Haselkorn, MD, MPH has disclosed no relevant financial relationships.

Kathleen Healey, NP, PhD has disclosed the following relevant financial relationship(s): Speakers Bureau: Teva Pharmaceuticals, Biogen.

Cheryl Hemingway, MBChB, PhD has disclosed no relevant financial relationships.

Robert Herndon, MD, has disclosed no relevant financial relationships.

Carrie Hersh, DO, MS has disclosed the following relevant financial relationship(s): Speakers Bureau: Teva Pharmaceuticals, Genzyme, a Sanofi Company; Contracted Research: Genentech.

Maria Houtchens, MD, MMsci has disclosed the following relevant financial relationship(s): Consulting Fee: Sanofi Aventis, Teva Pharmaceuticals, Genentech, Novartis; Contracted Research: Sanofi Aventis, Biogen.

Brian Hutchinson, PT, MSCS has disclosed the following relevant financial relationship(s): Speakers Bureau: Acorda Therapeutics.

Dina Jacobs, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Sanofi Genzyme; Contracted Research: Biogen.

Rosalind Kalb, PhD has disclosed no relevant financial relationships.

Stephen Kamin, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen; Contracted Research: Biogen, Novartis.

Adam Kaplin, MD, PhD has disclosed no relevant financial relationships.

Randy Karim, PT, DPT, NCS, CBIS has disclosed no relevant financial relationships.

Kenneth Kastaniegaard, PhD has disclosed no relevant financial relationships.

Ilana Katz Sand, MD has disclosed no relevant financial relationships.

Patricia Kennedy, RN, CNP, MSCN has disclosed no relevant financial relationships.

Dominique Kinnett-Hopkins, BA has disclosed no relevant financial relationships.

Thomas Korn, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Novartis, EMD Serono.

Lori Ann Kostich, MS CCC-SLP, MSCS has disclosed no relevant financial relationships.

Nicholas LaRocca, PhD has disclosed no relevant financial relationships.

Beverly Layton, RN, BSN, CCRC, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Bayer Healthcare Pharmaceuticals; Speakers Bureau: Biogen, Genzyme, a Sanofi Company.

Gus LaZear, MBA, CTRS has disclosed no relevant financial relationships.

Yvonne Learmonth, PhD, PT has disclosed no relevant financial relationships.

Yunju Lee, PhD has disclosed no relevant financial relationships.

David Li, MD, FRCPC has disclosed the following relevant financial relationship(s): Consulting Fee: Opexa Therapeutics; Speakers Bureau: Bayer Healthcare Pharmaceuticals, Novartis; Contracted Research: Roche, Sanofi Genzyme, Novartis, Perceptive, Sanofi Aventis.

Amy Lovett-Racke, PhD has disclosed the following relevant financial relationship(s): Contracted Research: TG Therapeutics.

Claudia Lucchinetti, MD has disclosed the following relevant financial relationship(s): Contracted Research: Biogen, Sanofi Genzyme, Mallinckrodt Pharmaceuticals, Novartis.

Christopher Luzzio, MD has disclosed no relevant financial relationships.

Heidi Maloni, PhD has disclosed no relevant financial relationships.

Kenneth Maravilla, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Guerbet, Bracco; Contracted Research: Guerbet.

Clyde Markowitz, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Bayer Healthcare Pharmaceuticals, Biogen, EMD Serono, Genentech, Genzyme, a Sanofi Company, Mylan Inc., Novartis, Roche, Sanofi Genzyme, Teva Pharmaceuticals.

Ruth Ann Marrie, MD, PhD has disclosed the following relevant financial relationship(s): Contracted Research:Sanofi Aventis.

Doreen Marshall, PhD has disclosed no relevant financial relationships.

Dorian McGavern, PhD has disclosed no relevant financial relationships.

Maureen Mealy, RN, BSN, MSCN, CNRN has disclosed no relevant financial relationships.

Deborah Miller, PhD, MSAA, LISW has disclosed no relevant financial relationships.

Marie Moore, MSN, FNP, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Genzyme, a Sanofi Company, Celgene; Speakers Bureau: Genzyme, a Sanofi Company.

Anne Morkholt, PhD has disclosed no relevant financial relationships.

Robert Motl, PhD has disclosed the following relevant financial relationship(s): Speakers Bureau: EMD Serono, Novartis; Contracted Research: Teva Neuroscience, EMD Serono, Biogen, Acorda Therapeutics, Sun Health, MC-10.

Ellen Mowry, MD, MCR has disclosed the following relevant financial relationship(s): Contracted Research: Biogen, Teva Pharmaceuticals.

Paolo Muraro, MD, PhD has disclosed no relevant financial relationships.

Marlene Murphy-Setzko, MD has disclosed the following relevant financial relationship(s): Speakers Bureau: Allergan.

Thomas Murray, MD has disclosed no relevant financial relationships.

Robert Naismith, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Acorda Therapeutics, Bayer Healthcare Pharmaceuticals, Biogen, EMD Serono, Genentech, Genzyme, a Sanofi Company, Novartis, Sanofi Genzyme.

Marie Namey, RN, MSN , MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Novartis, Genentech.

Sona Narula, MD has disclosed no relevant financial relationships.

Scott Newsome, DO, MSCS has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Genentech, Genzyme, a Sanofi Company; Contracted Research:Biogen, Genentech, Novartis.

Jacqueline Nicholas, MD, MPH has disclosed no relevant financial relationships.

John Nieland, PhD has disclosed no relevant financial relationships.

Patricia Pagnotta, ARNP, MSN, CNRN, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Sanofi Genzyme; Speakers Bureau: Acorda Therapeutics, Biogen, Mallinckrodt Pharmaceuticals, Sanofi Genzyme.

Sharon Peters, RN, BSN has disclosed no relevant financial relationships.

Laura Piccio, MD has disclosed the following relevant financial relationship(s): Speakers Bureau: Biogen; Other: Research funding from Alector.

Matthew Plow, PhD has disclosed no relevant financial relationships.

Alexandre Prat, MD, PhD, FRCPC has disclosed the following relevant financial relationship(s): Contracted Research: Teva Pharmaceuticals.

Francisco Quintana, PhD has disclosed no relevant financial relationships.

Michael Racke, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Coherus, Eisai, Cipla; Contracted Research: Genentech, Novartis, Actelion, Immune Tolerance Network; Other: Honoraria as Editor-in-Chief of Journal of Neuroimmunology.

Mary Jo Rajek, OT/L, MSCS has disclosed no relevant financial relationships.

Kottil Rammohan, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Acorda Therapeutics, Biogen, EMD Serono, Novartis, Roche/Genentech, Sanofi Aventis, Sanofi Genzyme, Teva Pharmaceuticals.

Mohini Ranganathan, MD has disclosed no relevant financial relationships.

Mary Rensel, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Genzyme, a Sanofi Company; Speakers Bureau: Biogen, Novartis, Genzyme, a Sanofi Company; Contracted Research: Medimmune.

John Rinker, II, MD has disclosed the following relevant financial relationship(s): Contracted Research: Biogen.

Jessica Robb, MD has disclosed no relevant financial relationships.

Derrick Robertson, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Genzyme, a Sanofi Company, Genentech, Novartis, Teva Pharmaceuticals; Speakers Bureau: Acorda Therapeutics, Biogen, EMD Serono, Genzyme, a Sanofi Company, Genentech, Mallinckrodt Pharmaceuticals, Novartis, Teva Pharmaceuticals; Contracted Research: Biogen, EMD Serono, Genentech, Genzyme, a Sanofi Company, Mallinckrodt Pharmaceuticals, Novartis.

Abdolmohamad Rostami, MD, PhD has disclosed no relevant financial relationships.

Matthew Sacco, PhD has disclosed no relevant financial relationships.

Amber Salter, PhD has disclosed no relevant financial relationships.

Randall Schapiro, MD, FAAN has disclosed the following relevant financial relationship(s): Salary: EMD Serono.

Eileen Scheid, RN, MSN, MSCN, CCRC has disclosed no relevant financial relationships.

Benjamin Segal, MD has disclosed the following relevant financial relationship(s): Contracted Research: Genentech.

Robert Shin, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Novartis, Sanofi Genzyme; Speakers Bureau: Biogen, Novartis, Sanofi Genzyme.

Lynne Shinto, ND, MPH has disclosed no relevant financial relationships.

Mark Skeen, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Genentech, EMD Serono, Genzyme, a Sanofi Company, Novartis; Speakers Bureau: Biogen, Novartis; Contracted Research: Novartis.

Dawn Smilek, MD, PhD has disclosed no relevant financial relationships.

Jennifer Smrcka, NP has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Genentech, Celgene, Genzyme, a Sanofi Company, EMD Serono; Speakers Bureau: Genentech, Genzyme, a Sanofi Company, Novartis, Teva Pharmaceuticals.

Olaf Stuve, MD, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Novartis, Sanofi Genzyme; Contracted Research: Teva Pharmaceuticals, Opexa Therapeutics; Other: Serves on Editorial Board: Multiple Sclerosis Journal; Therapeutic Advances in Neurological Disorders; Serves on Data Monitoring Committees without monetary compensation: Pfizer; TG Therapeutics.

Amy Sullivan, PsyD, ABPP has disclosed the following relevant financial relationship(s): Other: MS Cure Fund, NMSS.

Del Thomas, RN, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Celgene, Genzyme, Merck, Novartis, Roche, Teva.

Ben Thrower, MD has disclosed no relevant financial relationships.

Devin Tomiak has disclosed no relevant financial relationships.

Kathryn Tortorice, Pharm D, BCPS has disclosed the following relevant financial relationship(s): Royalty: (Spouse/Partner) Jones Bartlett Publishing; Consulting Fee: (Spouse/Partner) Seattle Genetics.

Ayman Tourbah, MD, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen Idec, Novartis, Medday Pharmaceuticals, Merck Serono, Hoffman LaRoche, Sanofi-Genzyme, Teva; Contracted Research: Biogen Idec, Novartis, Medday Pharmaceuticals, Merck Serono, Hoffman LaRoche, Sanofi-Genzyme, Teva; Honoraria: Biogen Idec, Novartis, Medday Pharmaceuticals, Merck Serono, Hoffman LaRoche, Sanofi-Genzyme, Teva; Travel Grants: Biogen Idec, Novartis, Medday Pharmaceuticals, Merck Serono, Hoffman LaRoche, Sanofi-Genzyme, Teva.

Anthony Trabousee, MD, FRCPC has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Roche, EMD Serono, Teva Pharmaceuticals; Contracted Research: Biogen, Chugai, CIHR, Roche, Michael Smith Foundation, MS Society of Canada.

Karen Vernon, RN, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Celgene, Genzyme, Merck, Novartis, Roche, Teva.

Peter Wade, MD has disclosed no relevant financial relationships.

Ari Waisman, PhD has disclosed the following relevant financial relationship(s): Royalty: Novartis.

Bryan Walker, MHS, PA-C has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, EMD Serono, Sanofi Genzyme; Speakers Bureau: Novartis.

Mitchell Wallin, MD, MPH has disclosed no relevant financial relationships.

Emmanuelle Waubant, MD, PhD has disclosed no relevant financial relationships.

Megan Weigel, DNP, ARNP-C, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Genentech, Genzyme, a Sanofi Company; Speakers Bureau: Acorda Therapeutics, EMD Serono, Genzyme, a Sanofi Company, Mallinckrodt Pharmaceuticals, Novartis, Pfizer, Teva Pharmaceuticals.

Brian Weinshenker, MD has disclosed the following relevant financial relationship(s): Royalty: RSR Ltd., Oxford University, MVZ Labor PD Dr. Volkmann und Kollegen GbR; Consulting Fee: MedImmune, Alexion.

Christopher Westphal, PhD has disclosed no relevant financial relationships.

Ellen Whipple, BS Pharm, PharmD has disclosed no relevant financial relationships.

Gail Widener, PhD has disclosed no relevant financial relationships.

Mary Alissa Willis, MD has disclosed the following relevant financial relationship(s): Speakers Bureau: Genzyme, a Sanofi Company, EMD Serono; Contracted Research: Biogen.

Dean Wingerchuk, MD, MSc, FRCPC has disclosed the following relevant financial relationship(s): Contracted Research: Alexion, TerumoBCT.

Jerry Wolinsky, MD has disclosed the following relevant financial relationship(s): Royalty: Millipore (Chemicon International) Corporation; Consulting Fee: Abbvie, Alkermes, Bayer Healthcare Pharmaceuticals, Celgene, Forward Pharma A/S, Novartis, Roche/Genentech, Sanofi Genzyme, Takeda, Teva Pharmaceuticals.

Sybil Wray, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, EMD Serono, Genentech, Sanofi Genzyme; Speakers Bureau: Biogen, Novartis, Sanofi Genzyme; Contracted Research: Biogen, Sanofi Genzyme, Actelion, Alkermes, Celgene, Genentech/Roche, TG Therapeutics.

Kathleen Zackowski, PhD, OTR has disclosed the following relevant financial relationship(s): Consulting Fee: Minoryx; Contracted Research: Minoryx.

Scott Zamvil, MD, PhD has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, EMD Serono, Novartis, Sanofi Genzyme, Teva Pharmaceuticals, Roche/Genentech; Contracted Research: Biogen, Celgene; Other: Serves on Data Safety Monitoring Boards; Lilly, BioMS, Teva Pharmaceuticals, Opexa Therapeutics.

PLATFORM PRESENTER DISCLOSURES

Caroline Altaras, BS has disclosed no relevant financial relationships.

James D. Bowen, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Acorda Therapeutics, Biogen, EMD Serono, Genzyme, a Sanofi Company, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals, Teva Neuroscience; Grant/Research Support: Acorda Therapeutics, Alexion, Allergan, Biogen, EMD Serono, Genzyme, a Sanofi Company, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals, Opexa, Osmotica, Roche, sanofi-aventis U.S. LLC, Xenoport; Honoraria: Acorda Therapeutics, Biogen, EMD Serono, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals, Pfizer Inc., Teva Neuroscience.

Margaret H. Cadden, MS has disclosed no relevant financial relationships.

Katie Cederberg, MS has disclosed no relevant financial relationships.

Thomas A. Edwards, BKin has disclosed the following relevant financial relationship(s): Grant/Research Support: Multiple Sclerosis Society of Canada, Consortium of Multiple Sclerosis Centers.

Jeffrey B. English, MD has disclosed no relevant financial relationships.

Debra I. Frankel, MS, OTR has disclosed no relevant financial relationships.

Helen Genova, PhD has disclosed no relevant financial relationships.

Colleen Harris, MN, NP, MSCN, MSCS has disclosed no relevant financial relationships.

Jessie Huisinga, PhD has disclosed the following relevant financial relationship(s): Grant/Research Support: National Multiple Sclerosis Society.

Amy Lovett-Racke, PhD has disclosed no relevant financial relationships.

Robert T. Naismith, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Acorda, Alkermes, Bayer, Biogen, EMD Seono, Genentech, Genzyme, Novartis and Teva; Grant/Research Support: NIH, NMSS.

Devyn Parsons, BSc has disclosed no relevant financial relationships.

Mary Ann Picone, MD has disclosed no relevant financial relationships.

Ruchika S. Prakash, PhD has disclosed the following relevant financial relationship(s): Grant/Research Support: National Multiple Sclerosis Society.

Kottil Rammohan, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Acorda Therapeutics, Biogen, EMD Serono, Novartis, Roche/Genentech, Sanofi Aventis, Sanofi Genzyme, Teva Pharmaceuticals.

Mary R. Rensel, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Genzyme, Novartis, TG Therapeutics; Grant/Research Support: NMSS.

Barry A. Singer, MD has disclosed the following relevant financial relationship(s): Consulting Fee: Acorda, Bayer, Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, Teva; Grant/Research Support: Acorda, Biogen, Sanofi Genzyme, MedImmune, Novartis, Roche.

Brett E. Skolnick, PhD has disclosed the following relevant financial relationship(s): Salary: Receptos, a wholly owned subsidiary of Celgene Corporation. Brett E. Skolnick, PhD is an employee of a commercial interest but will be speaking about early trial data for a product not available in the United States. This is an exemption to the rules regarding participation by commercial interest employees that is permitted by the ACCME.

Rachael Stacom, ANP, MSCN has disclosed the following relevant financial relationship(s): Consulting Fee: Teva, Genzyme, Serono. Fees for non-CME services from commercial interest or their agents: Teva, Genzyme, Serono.

Samantha Stephens, PhD has disclosed no relevant financial relationships.

Ana T. Todd, PhD, RN has disclosed no relevant financial relationships.

Karen VL Turpin, PhD Candidate, MSc, BScN has disclosed no relevant financial relationships.